PROVENTAI N T E R N A T I O N A L

1

TRACK 2 - MEDCHEM DESIGN & CUSTOM SYNTHESIS

TRACK 1 - MEDCHEMARTIFICIAL INTELLIGENCE / MACHINE LEARNING

TRACK 4 - MEDCHEM HIT TO LEAD IDENTIFICATION

TRACK 3 - MEDCHEM INTEGRATED DRUG DISCOVERY

TRACK 6 - MEDCHEMDISRUPTIVE TECHNOLOGIES

TRACK 5 - MEDCHEM CHEMICAL BIOLOGY & CHEMINFORMATICS

TRACK 8 - BIOLOGY DMPK & ADME

TRACK 7 - BIOLOGY OUTSOURCING FOR EMERGING BIOPHARMA

TRACK 10 - BIOLOGY IND- PROOF OF CONCEPT

TRACK 9 - BIOLOGY IN VIVO & IN VITRO PHARMACOLOGY

TRACK 12 - BIOLOGYTARGET VALIDATION

TRACK 11 - BIOLOGY STRATEGIC PARTNERSHIP & OUTSOURCING

2019 ATTENDEES

AGENDA BIOLOGY

AGENDA MED-CHEM

SPONSORS

Click here to find out what our clients think about our Strategy Meetings

Laurent AudolyCEO & FounderParthenon Therapeutics

Paul Peter Tak MD PhD President & CEO Kintai Therapeutics

Alun McCarthy Vice President C4X Discovery Ltd.

Vincent Lawton Chairman Addex Therapeutics

Tim Sparey CEO Novintum Bioscience

PJ Moloney CEO P4ML

Asif Ahmed Founder MirZyme Therapeutics

Tobias GabrielHead, External Science & Drug DiscoveryNovartis

Garry Pairaudeau Head of Hit Discovery AstraZeneca

Lassina BadoloDirector Discovery DMPK Merck

OUR UNIQUE ONLINE MEETING FORMAT CONTRIBUTORS TO THE AGENDA

Roundtable DiscussionsThese interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

Personalised AgendaEach delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.

One-to-one MeetingsThe most effective and time efficient way to assess potential partners at a strategic level. Gain access to our exclusive networking app to identify the people that you need to meet. The app will allow for instant anddirect messaging to organise online meetings during the dedicated time to most benefit you.

Strategic NetworkingStrategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

2020JUNESTRATEGY 29thONLINE MEETING

http://

BIOLOGYBIOLOGYMEDICINALCHEMISTRYMEDICINAL CHEMISTRY

&

PROVENTAI N T E R N A T I O N A L

1 GO TO MENU NEXT PAGEPREVIOUS PAGE

PRO-PARTNERS

VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE

CO-HOST

VISIT WEBSITE

VISIT WEBSITE

VISIT WEBSITE

VISIT WEBSITE

Dotmatics delivers a ready-to-use platform to capture, register, share, collaborate, query, visualise and analyse all the information and knowledge generated in the modern, highly collaborative scientific industries. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. The enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing.

LAXAI is a fully integrated contract research and development organization that delivers solutions in drug discovery, chemical process R&D, and GMP manufacturing for innovator pharmaceutical, Biotech, and animal health companies globally. Over the years, our focus has been on providing highly efficient scientific solutions, which has enabled us to partner on more than 20 integrated drug discovery programs and multiple medicinal chemistry focused FTE collaborations. As a result, we have delivered clinical candidates and technology platforms across diverse therapeutic areas. Further, owing to our strength in chemistry and our experience in solving complex problems, we have been engaged on a number of chemical process R&D and GMP manufacturing projects by innovator pharmaceutical companies. This experience, spanning more than a decade, has enabled us to develop deep expertise in custom NCEs, and custom manufactured advanced intermediates and fine chemicals.

Sai Life Sciences provides services to our pharma innovator partners, which accelerate the discovery,development and manufacture of complex small molecule therapeutics. Our clients gain clear competitive advantages through shorter time to market and risk minimization using our integrated and high-quality scientific services. Established in 1999, Sai has 2,000 employees located at 4 R&D and manufacturing sites in India. Sai has focused on building expert core capabilities in all areas of chemistry from hit discovery to GMP manufacturing. Sai also provides high-value integrated services in pharmacology, DMPK, toxicology and formulation development to better support the increasing needs of our customers.

VISIT WEBSITE

At Proventa Talent, we always look ahead to ensure that the service we deliver to you is second to none, both now and in the future. Proventa Talent based around our three key principles of commitment, intelligence and partnership ensures an unparalleled recruitment solution in the industry. We work with the leading talent in the field to offer a service of high quality, efficiency and transparency. In addition to this, our relationship with many organisations across the Life Sciences sector means that we are constantly developing our recruitment services to offer market-leading solutions including Contingency, Executive Search, Contract and fully integrated Recruitment Process Outsourcing to suit your short, medium and long term needs.

SPONSORSBIOLOGYMEDICINALCHEMISTRY

&

2 PROVENTAI N T E R N A T I O N A L

GO TO MENU

NETWORKING BREAK1 - 1 MEETING *13:30-13:50 G.M.T. NETWORKING BREAK

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUND TABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

12:00 - 12:30

19:20 - 20:20

14:30 - 15:30

18:00 - 19:00

13:30 - 14:30

19:00 - 19:20

12:30 - 13:30

15:30 - 17:30

17:30 - 18:00

1 - 1 MEETING *19:00-19:20 G.M.T.

KEYNOTE PRESENTATION KEYNOTE PRESENTATIONKEYNOTE PRESENTATION

Tobias Gabriel - HeadNovartis

Gokhan Yahioglu - Director MedChemAntikor Biopharma Ltd.

Mauro Marigo - Head Medicinal Chem.Endogena

Garry Pairaudeau - Head of Hit DiscoveryAstraZeneca

PJ Moloney - CEOP4ML

Tim Sparey - CEO Novintum Bioscience

Martin Swarbrick - Associate Director Cancer Research UK Therapeutic

Andy Merritt - Head of ChemistryLifeArc Centre

Raghava Reddy Kethiri, PhD., CSO

Tero Linnanen - Head Drug Disc.Fored Pharma

Jascha Blobel - CEO Molomics

Guy Lewy - CSO Sublime Therapeutics

NEXT PAGEPREVIOUS PAGE

Jonathan Hay - PartnerDelin Ventures

Marc Ramis - CEOSenolytic Therapeutics

TIME ( *G.M.T. ) AI & MACHINE LEARNING DESIGN & CUSTOM SYNTHESIS INTEGRATED DRUG DISCOVERY HIT TO LEAD IDENTIFICATIONCHEMICAL BIOLOGY & CHEMINFORMATICS DISRUPTIVE TECHNOLOGIES

Advances in drug discovery using AI

Can using AI reduce attrition rates in drug discovery?

Practical Advice on the Implementation of AI/ML in

Drug Discovery

0401 02 03 05 06

Generative algorithms & active learning approaches: enabling a more automated data-driven approach to

the design cycle

Making the molecule design cycle a success

Optimizing Chemical Reactions with Deep Reinforcement Learning

Activation of endogenous progenitor cells by small molecules, leading to

controlled tissue repair and regeneration

Accelerating translation through strategic alliances

Speeding the drug discovery process: collaborations, partnerships and Open

Access

How will AI enhance Drug Design: Challenges and opportunities

Hit and Lead Generation: Selection of screening sets and strategies to

maximise success rates

Providing unique chemical tools to probe kinetoplastid biology and as hit-to-lead candidates for drug

discovery

Cheminformatics Tools for Analysing & Designing Optimized Small-

Molecule Collections and Libraries

Molecular adventures in 3D and 4D: What new ground is being opened up

by cloud computing?

Connecting environmental exposure and neurodegeneration using

cheminformatics : potential and challenges

High-Throughput Screening vs Fragment Based Drug Discovery

How an integrated technology suite of solutions can improve compound

library acquisition and design

Targeting senescence cells

Laurent Audoly - CEO, FounderParthenon Therapeutics

TRACK & ROOM

7:00 - 7:30

14:20 - 15:20

9:30 - 10:30

13:00 - 14:00

8:30 - 9:30

14:00 - 14:20

7:30 - 8:30

10:30 - 12:30

12:30 - 13:00

TIME ( *E.T. )TRACK & ROOM

1 - 1 MEETING *13:50-14:10 G.M.T. 1 - 1 MEETING *14:10-14:30 G.M.T.

1 - 1 MEETING *15:30-15:50 G.M.T. 1 - 1 MEETING *16:10-16:30 G.M.T. 1 - 1 MEETING *16:50-17:10 G.M.T.1 - 1 MEETING *15:50-16:10 G.M.T. 1 - 1 MEETING *17:10-17:30 G.M.T.

KEYNOTE PRESENTATION KEYNOTE PRESENTATIONKEYNOTE PRESENTATION

MEDICINALCHEMISTRY

MEDICINAL CHEMISTRY AGENDA

3 PROVENTAI N T E R N A T I O N A L

BIOLOGY

BIOLOGY

GO TO MENU

Paul Peter Tak, MD PhD - Pres. & CEOKintai Therapeutics

Alun McCarthy - Vice PresidentC4X Discovery Ltd.

Vincent Lawton - Chairman Addex Therapeutics

NEXT PAGEPREVIOUS PAGE

How a shared-risked partnership model can

improve the success rates of getting to IND?

The Effect of Brexit on the Emerging Biopharm sector in

the UK.

How much influence do Investors play in making a decision on where to

Outsource? Cost vs Speed vs Quality?

The use of AI for decision making in drug discovery: How can applying AI in DMPK could impact in drug

discovery?

MetID and metabolite profiling

The right technology at the right time to conduct ADME/Tox screening of a drug candidate saving time & money in the process of obtaining regulatory

approval

Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug

Discovery

in vitro and in silico Approaches to Study Cytochrome P450-Mediated

Interactions.

Optimizing Chemical Reactions with Deep Reinforcement Learning

Bridging the gap between empirical drug discovery and rational drug development

How to get access to the secure enterprise ecosystem in order to

launch your PoC.

How to Complete a PoC without Depleting all Resources

Enabling business goals via collaborative or commercial

alliances, both moderates risk and garners reward

Which are the criteria of establishing successful partnership

and commercial alliances?

What is a validated target? Discussion on generating new

targets for drug discovery

Using Human Genetics to Identify Drug Targets

Guiding targets to success: Experiences progressing genetically validated targets through discovery

and development

OUTSOURCING FOR EMERGING BIOPHARMA DMPK & ADME IN VIVO & IN VITRO

PHARMACOLOGYIND- PROOF OF CONCEPT STRATEGIC PARTNERSHIP

& OUTSOURCING TARGET VALIDATION

07 08 09 10 11 12

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUND TABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

KEYNOTE PRESENTATION KEYNOTE PRESENTATIONKEYNOTE PRESENTATION

KEYNOTE PRESENTATION KEYNOTE PRESENTATIONKEYNOTE PRESENTATION

How to improve current alliances and gain more effective

collaborations

Asif Ahmed - FounderMirZyme Therapeutics

Lassina Badolo - Director Discovery Merck

Isabel Najera - CSOVirion Therapeutics

Marc Ramis - CEOSenolytic Therapeutics

Rob Howes - Director Discovery Biology AstraZeneca

Matthew Fyfe - Head of ChemistryVirion Therapeutics

12:00 - 12:30

19:20 - 20:20

14:30 - 15:30

18:00 - 19:00

13:30 - 14:30

19:00 - 19:20

12:30 - 13:30

15:30 - 17:30

17:30 - 18:00

TIME ( *G.M.T. )TRACK & ROOM

7:00 - 7:30

14:20 - 15:20

9:30 - 10:30

13:00 - 14:00

8:30 - 9:30

14:00 - 14:20

7:30 - 8:30

10:30 - 12:30

12:30 - 13:00

TIME ( *E.T. )TRACK & ROOM

NETWORKING BREAK1 - 1 MEETING *13:30-13:50 G.M.T. NETWORKING BREAK

1 - 1 MEETING *19:00-19:20 G.M.T.

1 - 1 MEETING *13:50-14:10 G.M.T. 1 - 1 MEETING *14:10-14:30 G.M.T.

1 - 1 MEETING *15:30-15:50 G.M.T. 1 - 1 MEETING *16:10-16:30 G.M.T. 1 - 1 MEETING *16:50-17:10 G.M.T.1 - 1 MEETING *15:50-16:10 G.M.T. 1 - 1 MEETING *16:30-16:50 G.M.T. 1 - 1 MEETING *17:10-17:30 G.M.T.

Marcie Glicksman - Head of Biology EnClear Therapies

AGENDA

PROVENTAI N T E R N A T I O N A L

4

Tobias GabrielHead, External Science & Drug

Discovery Novartis

ROUNDTABLE TOPIC

TIME SLOT (*GMT)12:30 - 13:30

Tim SpareyCEO

Novintum Bioscience

ROUNDTABLE TOPIC

TIME SLOT (*GMT)18:00 - 19:00

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*GMT)19:20 - 20:20

Laurent AudolyCEO & Founder

Parthenon Therapeutics

SPONSOR ROUNDTABLE TOPIC

Practical Advice on the Implementation of AI/ML in Drug Discovery

Tackling Noise and Uncertainty in DataDriven Drug Discovery Advances in drug discovery using AI

Can using AI reduce attrition rates in drug discovery?

LEARN MORE ABOUT OUR SPEAKERS

GO TO MENU NEXT PAGEPREVIOUS PAGE

TRACK 1 ARTIFICIAL INTELLIGENCE / MACHINE LEARNING

MEDICINALCHEMISTRY

PROVENTAI N T E R N A T I O N A L

5 GO TO MENU NEXT PAGEPREVIOUS PAGE

Gokhan YahiogluDirector of Medicinal Chemistry

Antikor Biopharma Ltd.

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Jascha BlobelCEO

Molomics

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

SPONSOR ROUNDTABLE TOPIC

Optimizing Chemical Reactions with Deep Reinforcement Learning

TOPIC TBC

Generative algorithms and active learning approaches: enabling a more

automated data-driven approach to the design cycle

Making the molecule design cycle a success

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

TRACK 2 DESIGN & CUSTOM SYNTHESIS

MEDICINALCHEMISTRY

PROVENTAI N T E R N A T I O N A L

6 GO TO MENU NEXT PAGEPREVIOUS PAGE

Mauro MarigoHead of Medicinal Chemistry

Endogena

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Martin SwarbrickAssociate Director

Cancer Research UK Therapeutic

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

SPONSOR ROUNDTABLE TOPIC

Speeding the drug discovery process: collaborations, partnerships and Open

Access

Internal vs. external drug discovery resources – what’s the most effective way

to advance a project?

Activation of endogenous progenitor cells by small molecules, leading to controlled

tissue repair and regeneration

Accelerating translation through strategic alliances

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

TRACK 3 INTEGRATED DRUG DISCOVERY

MEDICINALCHEMISTRY

PROVENTAI N T E R N A T I O N A L

7 GO TO MENU NEXT PAGEPREVIOUS PAGE

Garry PairaudeauHead of Hit Discovery

AstraZeneca

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Andy MerrittHead of Chemistry LifeArc Centre for

Therapeutics Discovery

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Raghava Reddy Kethiri, PhD. Chief Scientific Officer

LAXAI Life Science Pvt. Ltd.TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Tero LinnanenHead of Drug Discovery

Forendo Pharma

SPONSOR ROUNDTABLE TOPIC

Providing unique chemical tools to probe kinetoplastid biology and as hit-to-lead

candidates for drug discovery

TOPIC TBC

How will AI enhance Drug Design: Challenges and opportunities

Hit and Lead Generation: Selection of screening sets and strategies to maximise

success rates

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

TRACK 4 HIT TO LEAD IDENTIFICATION

MEDICINALCHEMISTRY

PROVENTAI N T E R N A T I O N A L

8 GO TO MENU NEXT PAGEPREVIOUS PAGE

SPEAKER TBC TBC TBC

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Guy LewyCSO

Sublime Therapeutics

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

SPONSOR ROUNDTABLE TOPIC

Connecting environmental exposure and neurodegeneration using cheminformatics:

potential and challenges

Software for Chemists: Desktop, Web and the Cloud

Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule

Collections and Libraries

Molecular adventures in 3D and 4D: What new ground is being opened up by

cloud computing?

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

TRACK 5 CHEMICAL BIOLOGY & CHEMINFORMATICS

MEDICINALCHEMISTRY

PROVENTAI N T E R N A T I O N A L

9 GO TO MENU NEXT PAGEPREVIOUS PAGE

PJ MoloneyCEO P4ML

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Jonathan HayPartner

Delin Ventures

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Marc RamisCEO

Senolytic Therapeutics

SPONSOR ROUNDTABLE TOPIC

Targeting senescence cells

TOPIC TBC

High-Throughput Screening vs Fragment Based Drug Discovery

How to turn disruptive techonologies into sucessful businessess

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

MEDICINALCHEMISTRY

TRACK 6 DISRUPTIVE TECHNOLOGIES

PROVENTAI N T E R N A T I O N A L

10 GO TO MENU NEXT PAGEPREVIOUS PAGE

Asif AhmedFounder

MirZyme Therapeutics

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Vincent LawtonChairman

Addex Therapeutics

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

SPONSOR ROUNDTABLE TOPIC

How much influence do Investors play in making a decision on where to Outsource?

Cost vs Speed vs Quality?

TOPIC TBC

How a shared-risked partnership model can improve the success rates of getting

to IND

The Effect of Brexit on the Emerging Biopharm sector in the UK.

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

TRACK 7 OUTSOURCING FOR EMERGING BIOPHARMA

BIOLOGY

PROVENTAI N T E R N A T I O N A L

11 GO TO MENU NEXT PAGEPREVIOUS PAGE

Lassina BadoloDirector Discovery DMPK

Merck

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

SPONSOR ROUNDTABLE TOPIC

chosing the right technology at the right time to conduct ADME/Tox screening of a drug candidate, to save time and money

in the process of obtaining regulatory approval

TOPIC TBC

The use of AI for decision making in drug discovery: How applying AI in DMPK could

impact drug discovery

MetID and metabolite profiling

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

TRACK 8 DMPK & ADME

BIOLOGY

PROVENTAI N T E R N A T I O N A L

12 GO TO MENU NEXT PAGEPREVIOUS PAGE

Isabel NajeraCSO

Virion Therapeutics

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPONSOR ROUNDTABLE TOPIC

Optimizing Chemical Reactions with Deep Reinforcement Learning

TOPIC TBC

Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery

in vitro and in silico Approaches to Study Cytochrome P450-Mediated Interactions.

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

Marcie GlicksmanHead of Biology

EnClear Therapies

TRACK 9 IN VIVO & IN VITRO PHARMACOLOGY

BIOLOGY

PROVENTAI N T E R N A T I O N A L

13 GO TO MENU NEXT PAGEPREVIOUS PAGE

Matthew FyfeHead of Chemistry and

Intellectual Property Sitryx Therapeutics

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

SPONSOR ROUNDTABLE TOPIC

How to Complete a PoC without Depleting all Resources

TOPIC TBC

Bridging the gap between empirical drug discovery and rational drug development

How to get access to the secure enterprise ecosystem in order to launch your PoC.

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

TRACK 10 IND- PROOF OF CONCEPT

BIOLOGY

PROVENTAI N T E R N A T I O N A L

14 GO TO MENU NEXT PAGEPREVIOUS PAGE

Marc RamisCEO

Senolytic Therapeutics

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Paul Peter Tak, MD PhDPresident & CEO

Kintai Therapeutics

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

SPONSOR ROUNDTABLE TOPIC

How to improve current alliances and gain more effective collaborations

TOPIC TBC

Enabling business goals via collaborative or commercial alliances, both moderates risk

and garners reward

Which are the criteria of establishing successful partnership and commercial

alliances?

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

TRACK 11 STRATEGIC PARTNERSHIP & OUTSOURCING

BIOLOGY

PROVENTAI N T E R N A T I O N A L

15 GO TO MENU NEXT PAGEPREVIOUS PAGE

Rob HowesDirector Discovery Biology

AstraZeneca

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

Alun McCarthyVice President

C4X Discovery Ltd.

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC

TIME SLOT (*GMT)

ROUNDTABLE TOPIC

TIME SLOT (*GMT)

SPONSOR ROUNDTABLE TOPIC

Guiding targets to success: Experiences progressing genetically validated targets through discovery

and development

TOPIC TBC

What is a validated target? Discussion on generating new targets

for drug discovery

Using Human Genetics to Identify Drug Targets

12:30 - 13:30

18:00 - 19:00

14:30 - 15:30

19:20 - 20:20

LEARN MORE ABOUT OUR SPEAKERS

BIOLOGY

TRACK 12 TARGET VALIDATION

PROVENTAI N T E R N A T I O N A L

16

COMPANY

AB-ScienceABAC Therapeutics AbbvieAbbvieAbbvie AlmirallAmcureAnnexin PharmaceuticalAstraZenecaAstraZenecaAstrazenecaAstrazenecaAstrazenecaAstrazenecaAstrazenecaAstraZenecaAstrazenecaAstrazenecaBarts Clinical Trials Unit, Queen Mary University of Lon-donBayerBayerBergenbioBiogenBoehringer Ingelheim RCV GmbH & Co KGBridge BiotecBridge BiotechBrunel University LondonC4X Discovery Ltd.C4X Discovery Ltd.C4X Discovery Ltd.Centauri TherapeuticsDe Montfort UniversityE Therapeutics PlcE-TherapeuticsE-Therapeutics

JOB TITLE

Head of Computational chemistryChief Executive Officer & Founder Senior Director, Discovery Platform TechnologiesHead of Discovery Chemistry and Screening biologyVice President and Distinguished Research Fellow, Discovery Chemistry and TechnologySection Head Medicinal Chemistry IIChief Executive OfficerChief Scientific Officer and Chief Medical OfficerVice President, Global Head of Structure, Biophysics & Frag-ment-Based lead GenerationGlobal Head Oncology SafetyExecutive DirectorAssociate Principal ScientistAssociate DirectorLead ScientistSenior Scientist/Lead ScientistSenior Director, Medicinal Chemistry Director, Medicinal ChemistryHead of Hit DiscoveryDirectorVice President, Head Research PharmacokineticsDirector, Medicinal ChemistryCSOHead of Computational ChemistryScientific Director – Group LeaderDirector/CEOCEO/DirectorHead of Department of Life SciencesCSOVP Structural Design & Medicinal ChemistryVP Medicinal ChemistryHead of ChemistryProfessor of Biomedical Science, and Head of Biomedical and Environmental Health ResearchBusiness Development & Programme ManagerPrincipal Data ScientistHead of Discovery Informatics

ElasmogenEli LillyEli LillyForendo PharmaGeneuroGlaxoSmithKlineGSKGSkGSKGSKGSKGSkGSKGSKGSKGSK IdorsiaIdorsiaImperial College LondonInventivaIpsenIpsenJanssenJanssen PharmaceuticaJohnson Johnson KalVista PharmaceuticalsKarus Therapeutics Leo Pharma LifeArcLifeArcLundbeckMerckMerckMerck KGaAMerck SeronoMerck Sharp and Dohme Mirzyme TherapeuticsMirZyme TherapeuticsMirZyme Therapeutics

Chief Executive Officer and Chief Scientific OfficerDirector, Emerging Technologies and InnovationSenior Research ScientistHead of Drug DiscoverySenior Vice President, Head of Preclinical DevelopmentSenior MetaData ManagerResearch DirectorUK Director Structural Biology & BiophysicsVP, Mechanistic Safety Scientific Project LeadershipBig Data AnalystScientific LeaderResearch Director/ Sr. FellowResearch DirectorScientific LeaderDirector, Medicinal ChemistryComputational ChemistDiscovery Scientist & Head of LaboratoryProfessor of Cancer BiologyHead of ChemistryDirector – Toxins In VitroPrincipal ScientistHead, Computational ChemistryComputational ChemistSenior Director – New Ventures and TransactionsDirector of Medicinal ChemistryChief Operations Officer & Chief Scientific Officer Vice President of Research Head of ChemistryPrincipal ScientistDirector and Head of Medicinal ChemistryExecutive Director, Global Head Quantitative PharmacologyDirector, Global Head of Search & Evaluation Discovery TechnologiesAssociate DirectorDirector Discovery DMPK Executive DirectorECODirector for R&DSenior scientist/Research Fellow

COMPANY JOB TITLE

GO TO MENU NEXT PAGEPREVIOUS PAGE

2019 ATTENDEES p.1BIOLOGYMEDICINALCHEMISTRY

&

PROVENTAI N T E R N A T I O N A L

17

COMPANY

NovartisNovartisNovartis Novo NordiskNovo NordiskOrion PharmaRedx PharmaRocheRocheRoche Innovation CenterSanofi

SanofiSanofiSanofiSanofiSentinel OncologySentinel Oncology LtdSilence TherapeuticsSosei HeptaresSummit TherapeuticsTopadur Pharma Topivert Pharma

JOB TITLE

Senior Investigator IInvestigator III / Lab Head Screening SciencesGlobal Head, External Science & Drug Discovery, Global Discovery ChemistryDirectorPrincipal Data ScientistDirector, Global Medicine DesignPrincipal ScientistGlobal Head Strategic Alliances, pRED InformaticsHead of Medicinal Chemistry Large Molecule Research Digital LeadVice President, Head of North America Diabetes and Cardiovascular Scientific Communications, North America Medical AffairsDirector Integrated Drug Discovery OutsourcingDirector, External Innovation in Drug DiscoverySection Head Small Molecular DesignHead External Innovation Drug DiscoveryDirector of ChemistryDirector of ChemistryVP, Head of Technology InnovationMedicinal Chemistry DirectorDirector, ChemistryChief Operating Officer Head of Biology

UCBUCBUCBUCLUniversity of BradfordUniversity of BristolUniversity of Central LancashireUniversity of GenevaUniversity of GlasgowUniversity of NottinghamUniversity of OxfordUniversity of SouthamptonUniversity of SurreyVernalisVertexVertexVifor PharmaVifor Pharma

Director, Structural Biology & BiophysicsDirector (Structural Biology and New Modalities)Principal Scientist CrystallographerSenior Research Associate/ Lead BiologistHead of Medicinal Chemistry Professor of Organic ChemistryChairman in BiosciencesProfessor and Director Professor of Chemical BiologyProfessor of Developmental PhysiologyMedicinal Chemistry AdvisorProfessor, Director of ResearchProfessor of RNA BiologyResearch DirectorPrincipal Research Fellow/ Head Biological SciencesHead of Chemistry, UKDirector and Head of ToxicologyHead of Chemical and Preclinical

COMPANY JOB TITLE

GO TO MENUPREVIOUS PAGE

2019 ATTENDEES p.2BIOLOGYMEDICINALCHEMISTRY

&